Accounts receivable, net (USD, thousands)

Inventory (USD, thousands)

Prepaid and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Goodwill (USD, thousands)

Intangible assets, net (USD, thousands)

Operating lease assets (USD, thousands)

Deferred tax assets (USD, thousands)

Investment and other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities (USD, thousands)

Current portion of long-term debt (USD, thousands)

Current portion of contingent consideration (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term debt, less current portion (USD, thousands)

Deferred income tax liabilities (USD, thousands)

Contingent consideration (USD, thousands)

Other long-term liabilities (USD, thousands)

Total liabilities (USD, thousands)

Total stockholders’ equity attributable to Bioventus Inc. (USD, thousands)

Noncontrolling interest (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

cb818d7681302a4107be55523196c61755ed84bf38183b196495627e7619e677

U.S.

- International

Total Revenue

7a60da1762d68c144852ab5ea770e0e30dcd6b0d46d17235820e696640be21f8

Net Sales (USD, thousands)

Cost of Sales (USD, thousands)

Gross Profit (USD, thousands)

Selling, General and Administrative Expense (USD, thousands)

Research and Development Expense (USD, thousands)

Change in Fair Value of Contingent Consideration (USD, thousands)

Loss on Disposals (USD, thousands)

Operating Income (Loss) (USD, thousands)

Interest Expense, Net (USD, thousands)

Other (Income) Expense (USD, thousands)

Other Expense (USD, thousands)

Loss Before Income Taxes (USD, thousands)

Income Tax (Benefit) Expense, Net (USD, thousands)

Net Loss (USD, thousands)

a268b54e1f3457a2efae6612d10dcc7f009be80972c8cb78474e48f8d8dedf70

Depreciation and Amortization (USD, thousands)

(Benefit) Provision for Expected Credit Losses (USD, thousands)

Equity-Based Compensation from 2021 Stock Incentive Plan (USD, thousands)

Unrealized (Gain) Loss on Foreign Currency Fluctuations (USD, thousands)

Other, Net (Operating Activities) (USD, thousands)

Net Cash from Operating Activities (USD, thousands)

Purchase of Property and Equipment (USD, thousands)

Investments and Acquisition of Distribution Rights (USD, thousands)

Net Cash from Investing Activities (USD, thousands)

Proceeds from Issuance of Class A and B Common Stock (USD, thousands)

Borrowing on Revolver (USD, thousands)

Payment on Revolver (USD, thousands)

Debt Financing Costs (USD, thousands)

Payments on Long-Term Debt (USD, thousands)

Other, Net (Financing Activities) (USD, thousands)

Net Cash from Financing Activities (USD, thousands)

Effect of Exchange Rate Changes on Cash (USD, thousands)

Net Change in Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Deferred Income Taxes (USD, thousands)

Accounts Receivable (USD, thousands)

Accounts Payable and Accrued Expenses (USD, thousands)

Other Current and Noncurrent Assets and Liabilities (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at the Beginning of the Period (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at the End of the Period (USD, thousands)

e849f3ee60e105a54ed3f98140734218cc286335922a03f7e1da410469cc071b

Pain Treatments

- U.S.

Restorative Therapies

Surgical Solutions

2e08233730e7549acb13b5ce9f38df366fbeed40d6c284038b1dc9e7d86d1c9d

Bioventus (BVS)

Financials